Background: Esthesioneuroblastoma (ENB), also known as olfactory neuroblastoma, is a rare sinonasal neuroectodermal malignancy with a slow onset of symptoms, favorable 5-year survival, and a propensity for delayed locoregional recurrence. Current treatment options include resection, adjuvant radiotherapy, and/or chemotherapy; however, because of its rarity and location, determining the optimal treatment for ENB has been challenging.
Observations: ENBs strongly express somatostatin receptors (SSTRs), particularly SSTR2, providing a molecular target for imaging and therapy.
Lessons: The authors present a case series of ENBs imaged with [68Ga]-DOTATATE PET/MRI and PET/CT and discuss the emerging role of [68Ga]-DOTATATE PET for ENB diagnosis, staging, and treatment response monitoring.
Keywords: CCRT = concurrent chemoradiation therapy; CT = computed tomography; ENB = esthesioneuroblastoma; FDG = fluorodeoxyglucose; LAR = long-acting release; MIP = maximum intensity projection; MRI = magnetic resonance imaging; NET = neuroendocrine tumor; PET; PET = positron emission tomography; PRRT; PRRT = peptide receptor radionuclide therapy; RT = radiotherapy; SSTR = somatostatin receptor; SUV = standardized uptake value; [177Lu]-DOTATATE; [68Ga]-DOTATATE; esthesioneuroblastoma; olfactory neuroblastoma.
© 2021 The authors.